'Do Your Job': To The Dismay Of Patients, FDA Panelists On Breast Implants Advise Better Risk Warnings, Not Recalls
Executive Summary
Despite pleas from breast implant patients at a March 25-26 US FDA advisory committee meeting for the agency to take off the market silicone and saline breast implants that have initiated a serious range of symptoms in some women, the panel instead recommended FDA get out stronger public advisories warning of the risks of breast implants and a lymphoma associated with the products.
You may also be interested in...
FDA Panel Recommends Against Approval Of Integra Mesh For Breast Reconstruction
The data supporting SurgiMend PRS ABDM isn’t enough to fully prove safety and effectiveness for that indication, the US FDA’s General and Plastic Surgery Devices Advisory Committee says.
FDA: Some Mesh Brands May Lead To More Complications In Breast Reconstruction Patients
Patients who receive breast reconstructive surgery using some brands of acellular dermal matrix seem to have a higher risk of major complications than those whose surgeries did not use the mesh, says a safety alert from the US FDA.
FDA Issues New Breast Implant Guidance While Giving Another A Nip And Tuck
The US FDA gives recommendations on the labeling of breast implants in a 29 September final guidance doc. The agency also revised a separate breast implant guidance last updated in 2006 to include, among other things, information found in the new labeling guidance.